Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial

Coleman, R, Hall, A, Albanell, J et al. (10 more authors) (2017) Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. The Lancet Oncology, 18 (11). pp. 1543-1552. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2017 Elsevier Ltd. All rights reserved. This is an author produced version of a paper published in The Lancet Oncology. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: November 2017
  • Accepted: 3 August 2017
  • Published (online): 13 October 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 12 Oct 2017 09:35
Last Modified: 29 Jun 2020 13:35
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S1470-2045(17)30603-4

Share / Export

Statistics